Literature DB >> 17406026

MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.

Pallavi Chaturvedi1, Ajay P Singh, Nicolas Moniaux, Shantibhushan Senapati, Subhankar Chakraborty, Jane L Meza, Surinder K Batra.   

Abstract

MUC4, a transmembrane mucin, is aberrantly expressed in pancreatic adenocarcinomas while remaining undetectable in the normal pancreas. Recent studies have shown that the expression of MUC4 is associated with the progression of pancreatic cancer and is inversely correlated with the prognosis of pancreatic cancer patients. In the present study, we have examined the phenotypic and molecular consequences of MUC4 silencing with an aim of establishing the mechanistic basis for its observed role in the pathogenesis of pancreatic cancer. The silencing of MUC4 expression was achieved by stable expression of a MUC4-specific short hairpin RNA in CD18/HPAF, a highly metastatic pancreatic adenocarcinoma cell line. A significant decrease in MUC4 expression was detected in MUC4-knockdown (CD18/HPAF-siMUC4) cells compared with the parental and scrambled short interfering RNA-transfected (CD18/HPAF-Scr) control cells by immunoblot analysis and immunofluorescence confocal microscopy. Consistent with our previous observation, inhibition of MUC4 expression restrained the pancreatic tumor cell growth and metastasis as shown in an orthotopic mouse model. Our in vitro studies revealed that MUC4-associated increase in tumor cell growth resulted from both the enhanced proliferation and reduced cell death. Furthermore, MUC4 expression was also associated with significantly increased invasiveness (P < or = 0.05) and changes in actin organization. The presence of MUC4 on the cell surface was shown to interfere with the tumor cell-extracellular matrix interactions, in part, by inhibiting the integrin-mediated cell adhesion. An altered expression of growth- and metastasis-associated genes (LI-cadherin, CEACAM6, RAC1, AnnexinA1, thrombomodulin, epiregulin, S100A4, TP53, TP53BP, caspase-2, caspase-3, caspase-7, plakoglobin, and neuregulin-2) was also observed as a consequence of the silencing of MUC4. In conclusion, our study provides experimental evidence that supports the functional significance of MUC4 in pancreatic cancer progression and indicates a novel role for MUC4 in cancer cell signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17406026     DOI: 10.1158/1541-7786.MCR-06-0353

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  85 in total

1.  Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies.

Authors:  Maria P Torres; Moorthy P Ponnusamy; Subhankar Chakraborty; Lynette M Smith; Srustidhar Das; Hwyda A Arafat; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-04-27       Impact factor: 6.261

Review 2.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

Review 3.  Structure, evolution, and biology of the MUC4 mucin.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Surinder K Batra
Journal:  FASEB J       Date:  2007-11-16       Impact factor: 5.191

Review 4.  Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.

Authors:  M Mimeault; S K Batra
Journal:  Gut       Date:  2008-10       Impact factor: 23.059

5.  Role of microRNA-150 in solid tumors.

Authors:  Fang Wang; Xiubao Ren; Xinwei Zhang
Journal:  Oncol Lett       Date:  2015-04-30       Impact factor: 2.967

6.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Subhankar Chakraborty; Subhash C Chauhan; Sangeeta Bafna; Jane L Meza; Pankaj K Singh; Michael A Hollingsworth; Parmender P Mehta; Surinder K Batra
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

7.  Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: potential role in therapy.

Authors:  Tomohiro Shimizu; María P Torres; Subhankar Chakraborty; Joshua J Souchek; Satyanarayana Rachagani; Sukhwinder Kaur; Muzafar Macha; Apar K Ganti; Ralph J Hauke; Surinder K Batra
Journal:  Cancer Lett       Date:  2013-03-21       Impact factor: 8.679

8.  Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.

Authors:  S Bafna; S Kaur; N Momi; S K Batra
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

9.  The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells.

Authors:  Heather C Workman; Jamie K Miller; Ellen Q Ingalla; Rouminder P Kaur; Diane I Yamamoto; Laurel A Beckett; Lawrence Jt Young; Robert D Cardiff; Alexander D Borowsky; Kermit L Carraway; Colleen Sweeney; Kermit L Carraway
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

10.  Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression.

Authors:  N Jonckheere; V Fauquette; L Stechly; N Saint-Laurent; S Aubert; C Susini; G Huet; N Porchet; I Van Seuningen; P Pigny
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.